CN110234342A - 组合疗法 - Google Patents
组合疗法 Download PDFInfo
- Publication number
- CN110234342A CN110234342A CN201780084564.XA CN201780084564A CN110234342A CN 110234342 A CN110234342 A CN 110234342A CN 201780084564 A CN201780084564 A CN 201780084564A CN 110234342 A CN110234342 A CN 110234342A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- compound
- cell
- prmt5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662428764P | 2016-12-01 | 2016-12-01 | |
US62/428,764 | 2016-12-01 | ||
US201662433363P | 2016-12-13 | 2016-12-13 | |
US62/433,363 | 2016-12-13 | ||
PCT/IB2017/057549 WO2018100535A1 (fr) | 2016-12-01 | 2017-11-30 | Polythérapie |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110234342A true CN110234342A (zh) | 2019-09-13 |
Family
ID=60782286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780084564.XA Pending CN110234342A (zh) | 2016-12-01 | 2017-11-30 | 组合疗法 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3548068A1 (fr) |
JP (1) | JP2020511407A (fr) |
KR (1) | KR20190090823A (fr) |
CN (1) | CN110234342A (fr) |
AU (1) | AU2017369994A1 (fr) |
BR (1) | BR112019011350A2 (fr) |
CA (1) | CA3045243A1 (fr) |
WO (1) | WO2018100535A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
WO2021225963A2 (fr) * | 2020-05-04 | 2021-11-11 | Sanford Burnham Prebys Medical Discovery Institute | Méthodes et compositions d'induction d'immunité antitumorale |
EP4149483A4 (fr) * | 2020-05-15 | 2024-09-11 | Fred Hutchinson Cancer Center | Compositions et méthodes d'amélioration d'immunothérapie du cancer |
CN113908283A (zh) * | 2021-09-30 | 2022-01-11 | 上海交通大学医学院附属新华医院 | Prmt5抑制剂及其与pd-l1抗体阻断剂联合在治疗肺癌上的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103221427A (zh) * | 2010-08-23 | 2013-07-24 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
WO2014100719A2 (fr) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
WO2016145150A2 (fr) * | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Traitement sélectif de cancer dépendant de prmt5 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
PT2112166T (pt) | 1998-12-23 | 2019-01-30 | Pfizer | Anticorpos monoclonais humanos contra ctla-4 |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
WO2003068819A1 (fr) | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Methode de generation de lymphocytes precurseurs de vertebres genetiquement modifies et leur utilisation dans la production de proteines de liaison heterologues |
IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
US7550140B2 (en) | 2002-06-13 | 2009-06-23 | Crucell Holland B.V. | Antibody to the human OX40 receptor |
AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
CA2508660C (fr) | 2002-12-23 | 2013-08-20 | Wyeth | Anticorps anti pd-1 et utilisations |
EP2270051B1 (fr) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Anticorps spécifiques de PD-1 et CD3 humains |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
WO2006063067A2 (fr) | 2004-12-09 | 2006-06-15 | La Jolla Institute For Allergy And Immunology | Nouveau domaine de regulation du recepteur tnf |
NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
US20080286286A1 (en) | 2006-01-13 | 2008-11-20 | Board Of Regents, The University Of Texas System | Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor |
GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
SI2851374T1 (sl) | 2007-12-14 | 2017-08-31 | Bristol-Myers Squibb Company | Vezavne molekule k humanemu ox40 receptorju |
EP2262837A4 (fr) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
EP2342228B1 (fr) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Anticorps spécifiques de pd-1 et leurs utilisations |
US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
CA2992770A1 (fr) | 2009-11-24 | 2011-06-03 | Medimmune Limited | Agents de liaison cibles diriges contre b7-h1 |
US9044432B2 (en) | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
EP2748199B1 (fr) | 2011-08-23 | 2019-08-28 | Board of Regents, The University of Texas System | Anticorps anti-ox40 et leurs procédés d'utilisation |
EA036814B9 (ru) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение |
SG11201407190TA (en) * | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
MX370848B (es) | 2012-10-04 | 2020-01-08 | Dana Farber Cancer Inst Inc | Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso. |
US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
WO2014100730A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de la prmt5 contenant une dihydro- ou tétrahydro-isoquinoléine et leurs utilisations |
US20150344457A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | Methods of inhibiting prmt5 |
US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
-
2017
- 2017-11-30 BR BR112019011350A patent/BR112019011350A2/pt not_active IP Right Cessation
- 2017-11-30 KR KR1020197018433A patent/KR20190090823A/ko unknown
- 2017-11-30 JP JP2019529614A patent/JP2020511407A/ja not_active Withdrawn
- 2017-11-30 AU AU2017369994A patent/AU2017369994A1/en not_active Abandoned
- 2017-11-30 EP EP17818288.7A patent/EP3548068A1/fr not_active Withdrawn
- 2017-11-30 CN CN201780084564.XA patent/CN110234342A/zh active Pending
- 2017-11-30 WO PCT/IB2017/057549 patent/WO2018100535A1/fr unknown
- 2017-11-30 CA CA3045243A patent/CA3045243A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103221427A (zh) * | 2010-08-23 | 2013-07-24 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
WO2014100719A2 (fr) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
WO2016145150A2 (fr) * | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Traitement sélectif de cancer dépendant de prmt5 |
Non-Patent Citations (2)
Title |
---|
丁兆军等: "《大肠癌基础与临床》", 31 August 2007 * |
罗举等: "蛋白质精氨酸甲基转移酶与相关疾病", 《国际病理科学与临床杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
Also Published As
Publication number | Publication date |
---|---|
CA3045243A1 (fr) | 2018-06-07 |
EP3548068A1 (fr) | 2019-10-09 |
KR20190090823A (ko) | 2019-08-02 |
AU2017369994A1 (en) | 2019-06-13 |
JP2020511407A (ja) | 2020-04-16 |
BR112019011350A2 (pt) | 2019-10-22 |
WO2018100535A1 (fr) | 2018-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7523084B2 (ja) | 抗ガレクチン-9抗体及びその使用 | |
CN110234342A (zh) | 组合疗法 | |
CN108290946A (zh) | 抗tigit抗体和使用方法 | |
CN108348521A (zh) | 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
CN110087680A (zh) | 使用包含btk抑制剂的组合产品治疗癌症 | |
JP2018516884A (ja) | コルチスタチン誘導体による治療に対する患者の標的化選択 | |
JP2020517652A5 (fr) | ||
US20230094076A1 (en) | Combination therapy | |
JP2022551662A (ja) | Bcmaを標的とする、ヒトサルの交差反応性を有するヒト化モノクローナル抗体 | |
JP2023075286A (ja) | 癌を治療するためのii型タンパク質アルギニンメチルトランスフェラーゼ阻害剤及びicos結合タンパク質の組合せ | |
WO2017112823A1 (fr) | Sélection ciblée de patients en vue d'un traitement avec des dérivés de cortistatine spécifiques | |
JP2022502079A (ja) | がん関連抗体組成物および使用方法 | |
US20190350931A1 (en) | Combination therapy | |
CN112469441A (zh) | 用icos结合蛋白和精氨酸甲基转移酶抑制剂的组合疗法 | |
JP2016155776A (ja) | 抗腫瘍効果増強剤および抗腫瘍剤 | |
RU2810002C2 (ru) | Однодоменные антитела, направленные против внутриклеточных антигенов | |
KR20240058146A (ko) | 항체-약물 접합체, 이의 제조 방법 및 의약적 용도 | |
CN115998900A (zh) | 抗trop-2抗体药物偶联物及其医药用途 | |
JP2021508709A (ja) | 疾患及び障害の治療及び予防のための抗レナラーゼ抗体 | |
TW202426492A (zh) | 抗tigit抗體及使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190913 |
|
WD01 | Invention patent application deemed withdrawn after publication |